インデックス付き
- Jゲートを開く
- Genamics JournalSeek
- アカデミックキー
- ジャーナル目次
- グローバル インパクト ファクター (GIF)
- 中国国家知識基盤 (CNKI)
- ウルリッヒの定期刊行物ディレクトリ
- レフシーク
- ハムダード大学
- エブスコ アリゾナ州
- OCLC-WorldCat
- パブロン
- ジュネーブ医学教育研究財団
- ユーロパブ
- Google スカラー
このページをシェアする
ジャーナルチラシ
概要
Quality Verification of Dendritic Cell-Based Cancer Vaccine
Shigetaka Shimodaira, Terutsugu Koya, Yumiko Higuchi, Masato Okamoto and Shigeo Koido
In the era of personalized cancer therapy, immunotherapy is now emerging as a potential option. Therapeutic cancer vaccination has been developed for the induction of an efficient immune response targeting tumor-associated antigens. The efficacy of dendritic cell (DC)-based vaccines is attributed to their ability to induce immunity against cancers. Criteria for the approval of therapeutically active DCs, such as their viability and purity, are here verified based on phenotypic characteristics, linked to their antigen-presenting ability and functional analyses of phagocytosis and pinocytosis. A standardized phenotype of DCs harboring bioactive functions would be useful to provide personalized vaccines for cancer immunotherapy.